Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis

por Emery, Paul, Tanaka, Yoshiya, Cardillo, Tracy, Schlichting, Douglas, Rooney, Terence, Beattie, Scott, Helt, Cameron, Smolen, Josef S.
Publicado 2020

Correction to: Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis

por Emery, Paul, Tanaka, Yoshiya, Cardillo, Tracy, Schlichting, Douglas, Rooney, Terence, Beattie, Scott, Helt, Cameron, Smolen, Josef S.
Publicado 2020

Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids

por van Vollenhoven, Ronald, Helt, Cameron, Arora, Vipin, Zhong, Jinglin, Correia, Ana Pinto, de la Torre, Inma, Muram, David
Publicado 2018

Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT...

por Coates, Laura C., Mease, Philip, Kronbergs, Andris, Helt, Cameron, Sandoval, David, Park, So Young, Combe, Bernard, Nash, Peter, Deodhar, Atul
Publicado 2022

Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-...

por Coates, Laura C., Mease, Philip, Kronbergs, Andris, Helt, Cameron, Sandoval, David, Park, So Young, Combe, Bernard, Nash, Peter, Deodhar, Atul
Publicado 2022